Review
Immunology
Lifei Liang, Xiaoqing Xu, Jiawei Li, Cheng Yang
Summary: This review summarizes and discusses the bidirectional regulation between miRNAs and MDSCs in the tumor microenvironment, revealing the impact of miRNAs and MDSCs on tumor immune escape and metastasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Elham Shokati, Elahe Safari
Summary: MDSCs have been shown to play a role in tumor progression and metastasis in the tumor microenvironment by downregulating anti-tumor immune responses. Exosomal miRNAs released by MDSCs and tumor cells mediate the immunosuppressive characteristics of MDSCs, but their role in MDSCs differentiation and function in the tumor microenvironment requires further investigation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Estefania Prochetto, Eliana Borgna, Carlos Jimenez-Cortegana, Victor Sanchez-Margalet, Gabriel Cabrera
Summary: Myeloid-derived suppressor cells (MDSCs) play a role in both pathological and non-pathological conditions, including cancer, infections, pregnancy, aging, and vaccination. Vaccination is a crucial public health measure, but the presence of MDSCs may impact vaccine efficacy.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Oncology
Zhaonian Hao, Ruyuan Li, Yuanyuan Wang, Shuangying Li, Zhenya Hong, Zhiqiang Han
Summary: MDSC play vital roles in cancer microenvironment, influencing the responses to immunotherapies and prognosis of cancer patients. Therefore, proposing MDSC-inhibiting strategies becomes crucial in the field of cancer immunotherapies.
BIOMARKER RESEARCH
(2021)
Review
Immunology
Xidan Gao, Hongshu Sui, Shang Zhao, Xingmei Gao, Yanping Su, Peng Qu
Summary: MDSCs, a heterogeneous population of immature myeloid cells accumulating in tumor-bearing hosts, play a critical role in promoting tumor immune escape. Therapeutic strategies targeting MDSCs have shown potential in enhancing the efficacy of tumor immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell Biology
Tianmiao Ma, Bernhard W. Renz, Matthias Ilmer, Dominik Koch, Yuhui Yang, Jens Werner, Alexandr V. Bazhin
Summary: Myeloid-derived suppressor cells (MDSCs) play a crucial role in the tumor microenvironment (TME) and have been linked to poor prognosis and drug resistance in cancer. Further research is needed to fully understand the definition and phenotypes of MDSCs in humans.
Article
Oncology
Yu Chen, Yanquan Xu, Huakan Zhao, Yu Zhou, Jiangang Zhang, Juan Lei, Lei Wu, Mingyue Zhou, Jingchun Wang, Shuai Yang, Xiao Zhang, Guifang Yan, Yongsheng Li
Summary: Cancer immunotherapy targeting myeloid-derived suppressor cells (MDSCs) is a promising anti-cancer strategy. This study explored the regulatory mechanisms of cholesterol metabolic reprogramming in MDSCs and found that cholesterol deficiency increased the immunosuppressive activity of MDSCs. Mechanistically, cholesterol elimination induced nuclear accumulation of LXR beta and enhanced the binding of LXR beta-RXR alpha on Arg1 promoter. Furthermore, itraconazole improved MDSC immunosuppressive activity and promoted tumor growth by inhibiting the RIPK3-AKT-mTORC1 pathway and impeding cholesterol synthesis.
Article
Immunology
Ge Song, Yue Zhang, Jie Tian, Jie Ma, Kai Yin, Huaxi Xu, Shengjun Wang
Summary: Myeloid-derived suppressor cells (MDSCs) are a major component of tumor-induced immunosuppressive environment, and TRAF6 plays a critical role in modulating the immunosuppressive function of MDSCs by mediating K63-linked polyubiquitination and phosphorylation of STAT3. The abnormal accumulation of MDSCs in the peripheral blood of lung cancer patients, with highly expressed TRAF6 and arginase 1, suggests a potential target for antitumor immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Peng Dong, Yu Yan, Yujun Fan, Hui Wang, Danzhu Wu, Liyuan Yang, Junpeng Zhang, Xiaoyang Yin, Yajuan Lv, Jiandong Zhang, Yuzhu Hou, Fengjun Liu, Xinshuang Yu
Summary: Pancreatic cancer has a high mortality rate and early symptoms are difficult to detect, leading to a late-stage diagnosis for most patients. Current conventional treatments have limited efficacy, and the tumor microenvironment plays a crucial role in tumor progression. Myeloid-derived suppressor cells are key components in the tumor microenvironment and targeting them is important for effective treatment.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Article
Engineering, Biomedical
Wenxi Zhou, Xinli Chen, Yu Zhou, Si Shi, Chen Liang, Xianjun Yu, Hongyi Chen, Qin Guo, Yiwen Zhang, Peixin Liu, Chao Li, Yongchao Chu, Yifan Luo, Yu Wang, Zheng Zhou, Zhenhao Zhao, Qinjun Chen, Tao Sun, Chen Jiang
Summary: This study proposes a strategy to derive exosomes from immunogenically dying tumor cells and utilize them for various purposes, including antigen presentation and cargo delivery of vaccines against pancreatic cancer. The results demonstrate that these exosomes can serve as an effective prophylactic vaccine and combining them with chemotherapy can enhance therapeutic effects.
Article
Multidisciplinary Sciences
Dhifaf Sarhan, Silke Eisinger, Fei He, Maria Bergsland, Catarina Pelicano, Caroline Driescher, Kajsa Westberg, Itziar Ibarlucea Benitez, Rawan Humoud, Giorgia Palano, Shuijie Li, Valentina Carannante, Jonas Muhr, Bjorn Onfelt, Susanne Schlisio, Jeffrey Ravetch, Rainer Heuchel, Matthias J. Lohr, Mikael C. Karlsson
Summary: Immunotherapy for cancer has revolutionized the treatment of previously lethal cancers, but its efficacy in pancreatic ductal adenocarcinoma (PDAC) has been disappointing. This study shows that the expression of scavenger receptor MARCO is associated with poor prognosis and a tumor phenotype that excludes lymphocytes. Targeting MARCO can remodel the tumor microenvironment and improve the efficiency of immunotherapy in PDAC patients.
Article
Oncology
Ting Zhao, Sheng Liu, Nasser H. Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du
Summary: Understanding the mechanisms of MDSC biogenesis, particularly the role of LAL, can facilitate the diagnosis and prognosis of cancer, as well as the development of targeted immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Zhuang Chen, Rui Yuan, Shengyun Hu, Weitang Yuan, Zhenqiang Sun
Summary: This review provides a comprehensive description of the characteristics, functions, and mechanisms of myeloid-derived suppressor cell exosomes (MDSCs-Exos) in tumor immunity. MDSCs-Exos show similar immunosuppressive, angiogenesis, and metastatic effects as parental MDSCs. Immunotherapy targeting MDSCs-Exos has great potential in both cancer and non-cancerous diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yang Zhao, Junfeng Du, Xiaofei Shen
Summary: Myeloid-derived suppressor cells (MDSCs) are a major negative regulator in tumor microenvironment (TME) by inhibiting immune response and promoting immunosuppression. This review focuses on the features of MDSCs in TME and potential targets for tumor immunotherapy. Therapies aiming to reprogram TME, prevent MDSC immunosuppression, promote MDSC differentiation, and impact MDSC recruitment and abundance in tumor site are discussed. Combinatorial strategies to improve clinical efficacy and outcomes of cancer patients through better understanding of MDSCs generation and suppression in TME are also summarized.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Maria Luisa Sanchez-Leon, Carlos Jimenez-Cortegana, Gabriel Cabrera, Elba Monica Vermeulen, Luis de la Cruz-Merino, Victor Sanchez-Margalet
Summary: Dendritic cells (DCs) play a diminished role in various malignancies due to immunosuppressive conditions in the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs) accumulate in the TME and inhibit DC functions, maturation, and development. DC-based vaccines have been developed to improve antitumor immunity, and their effectiveness in murine models and cancer patients, alone or in combination with other treatments, has been explored.
FRONTIERS IN IMMUNOLOGY
(2022)